Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6388-6393

  Pratesi, Graziella ^a   Petrangolini, Giovanna ^a   Tortoreto, Monica ^a   Addis, Alessandro ^b   Belluco, Sara ^b   Rossini, Anna ^a   Selleri, Silvia ^b   Rumio, Cristiano ^b   Menard, Sylvie ^a   Balsari, Andrea ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; IMMUNOSTIMULATING AGENT; OLIGODEOXYNUCLEOTIDE DERIVATIVE; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; IMMUNOSTIMULATION; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; ORTHOTOPIC TRANSPLANTATION; PANCREAS CARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CPG ISLANDS; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; OLIGONUCLEOTIDES; PANCREATIC NEOPLASMS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 9; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22244438547     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0602     Document Type: Article

References (27)

1. El-Rayes BF, Shields AF, Vaitkevicius V, Philip PA. Developments in the systemic therapy of pancreatic cancer. Cancer Invest 2003;21:73-86.
2. Burris H, Moore M, Andersen J, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Goldstein D, Carroll S, Apte M, Keogh G. Modern management of pancreatic carcinoma. Intern Med J 2004;34:475-81.
4. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002;14:103-10.
5. Rumio C, Besusso D, Palazzo M, et al. Degranulation of Paneth cells via toll-like receptor 9. Am J Pathol 2004;165:373-81.
6. Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol 2004;172:3173-80.
7. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 2004;173:2280-7.
8. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:659-60.
9. Sfondrini L, Besusso D, Zoia MT, et al. Absence of the CD1 molecule up-regulates anticumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol 2002;169:151-8.
10. Balsari A, Tortoreto M, Besusso D, et al. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004;40:1275-81.
11. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic marine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105-14.
12. Mitas L, Mason KA, Ariga H, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004;64:5074-7.
13. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucteotides. Curr Oncol Rep 2004;6:88-95.
14. Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003;9:2693-700.
15. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998;95:15553-8.
16. Johansson EL, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 1998;66:514-20.
17. Grant AG, Duke D, Hermon-Taylor J. Establishment and characterization of primary human pancreatic carcinoma in continuous cell culture and in nude mice. Br J Cancer 1979;39:143-51.
18. United Kingdom Coordinating Committee on Cancer Research (UKCCCR), Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd edition). Br J Cancer 1998;77:1-10.
19. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1:50-62.
20. Liu L, Zhou X, Shi J, Xie X, Yuan Z. Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin. Immunology 2003;110:341-7.
21. Corbett TH, Griswold DP, Wolpert MK, Venditti JM, Schabel FM. Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rev 1979;63:799-801.
22. Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis 1993;11:5-14.
23. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249-58.
24. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immune-surveillance and immunotherapy. Nat Immunol 2001;2:293-9.
25. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotide cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999-1006.
26. Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001;69:81-8.
27. Schneider C, Schmidt T, Ziske C, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004;53:355-61.